# David C Rees

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 210 papers | 7,805 citations | 42 h-index | 84 g-index |
| 226 ext. papers | 9,286 ext. citations | 6 avg, IF | 6.12 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 210 | Venous cerebral blood flow quantification and cognition in patients with sickle cell anemia.. *Journal of Cerebral Blood Flow and Metabolism*, **2022**, 271678X211072391 | 7.3 | 2 |
| 209 | Automating Pitted Red Blood Cell Counts Using Deep Neural Network Analysis: A New Method for Measuring Splenic Function in Sickle Cell Anaemia.. *Frontiers in Physiology*, **2022**, 13, 859906 | 4.6 | 1 |
| 208 | Individual Watershed Areas in Sickle Cell Anemia: An Arterial Spin Labeling Study.. *Frontiers in Physiology*, **2022**, 13, 865391 | 4.6 | 1 |
| 207 | Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). *Haematologica*, **2021**, 106, 1770-1773 | 6.6 | 3 |
| 206 | Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). *Blood*, **2021**, 138, 12-12 | 2.2 | |
| 205 | Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia. *British Journal of Haematology*, **2021**, | 4.5 | 1 |
| 204 | Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trial. *Trials*, **2021**, 22, 690 | 2.8 | 0 |
| 203 | A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease. *Haematologica*, **2021**, | 6.6 | 2 |
| 202 | Pitfalls in the Diagnosis of Thalassemia Intermedia. *Hemoglobin*, **2021**, 45, 265-268 | 0.6 | |
| 201 | Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistance. *Nature Communications*, **2021**, 12, 1792 | 17.4 | 5 |
| 200 | Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease. *Orphanet Journal of Rare Diseases*, **2021**, 16, 148 | 4.2 | 0 |
| 199 | Oxidative status in the thalassemia syndromes in Sri Lanka; a cross-sectional survey. *Free Radical Biology and Medicine*, **2021**, 166, 337-347 | 7.8 | 2 |
| 198 | Improving the laboratory diagnosis of pyruvate kinase deficiency. *British Journal of Haematology*, **2021**, 193, 994-1000 | 4.5 | 0 |
| 197 | A Sri Lankan girl with a new genetic variant in the PKLR gene causing pyruvate kinase deficiency: a case report. *Journal of Medical Case Reports*, **2021**, 15, 374 | 1.2 | |
| 196 | Clinical management of sickle cell liver disease in children and young adults. *Archives of Disease in Childhood*, **2021**, 106, 315-320 | 2.2 | 4 |
| 195 | Long-term oxygen therapy in children with sickle cell disease and hypoxaemia. *Archives of Disease in Childhood*, **2021**, 106, 258-262 | 2.2 | 1 |
| 194 | Pathophysiological Relevance of Renal Medullary Conditions on the Behaviour of Red Cells From Patients With Sickle Cell Anaemia. *Frontiers in Physiology*, **2021**, 12, 653545 | 4.6 | 1 |

| | | | |
|---|---|---|---|
| 193 | What does the term Qickle cell diseaseQmean?. *British Journal of Haematology*, **2021**, | 4.5 | |
| 192 | Beneficial effects of adenotonsillectomy in children with sickle cell disease. *ERJ Open Research*, **2020**, 6, | 3.5 | 2 |
| 191 | Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review. *BMJ Paediatrics Open*, **2020**, 4, e000690 | 2.4 | 2 |
| 190 | Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. *New England Journal of Medicine*, **2020**, 382, 2289-2301 | 59.2 | 152 |
| 189 | Commentary on sickle cell non-invasive prenatal testing article. *British Journal of Haematology*, **2020**, 190, 20-21 | 4.5 | 1 |
| 188 | Emerging therapies in sickle cell disease. *British Journal of Haematology*, **2020**, 190, 149-172 | 4.5 | 16 |
| 187 | COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital. *Haematologica*, **2020**, 105, 2691-2693 | 6.6 | 21 |
| 186 | Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. *Orphanet Journal of Rare Diseases*, **2020**, 15, 177 | 4.2 | 3 |
| 185 | Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. *British Journal of Haematology*, **2020**, 189, 24-38 | 4.5 | 16 |
| 184 | Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 22-24 | 2.2 | |
| 183 | Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. *Blood*, **2020**, 136, 13-13 | 2.2 | 1 |
| 182 | Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. *Haematologica*, **2020**, 105, 2651-2654 | 6.6 | 20 |
| 181 | EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. *Hepatology*, **2020**, 71, 1546-1558 | 11.2 | 50 |
| 180 | National comparative audit of blood transfusion: 2014 audit of transfusion services and practice in children and adults with sickle cell disease. *Transfusion Medicine*, **2020**, 30, 186-195 | 1.3 | 2 |
| 179 | Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. *Archives of Disease in Childhood*, **2020**, 105, 575-579 | 2.2 | 3 |
| 178 | Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apoliprotein E. *Circulation Genomic and Precision Medicine*, **2020**, 13, 531-540 | 5.2 | 2 |
| 177 | The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia. *British Journal of Haematology*, **2019**, 186, 879-886 | 4.5 | 3 |
| 176 | Index of Pain Experience in Sickle Cell Anaemia (IPESCA): development from daily pain diaries and initial findings from use with children and adults with sickle cell anaemia. *British Journal of Haematology*, **2019**, 186, 360-363 | 4.5 | 1 |

| | | | |
|---|---|---|---|
| 175 | The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia. *Physiological Reports*, **2019**, 7, e14027 | 2.6 | 7 |
| 174 | Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. *New England Journal of Medicine*, **2019**, 380, 549-558 | 59.2 | 135 |
| 173 | The Effect of Antioxidants on the Properties of Red Blood Cells From Patients With Sickle Cell Anemia. *Frontiers in Physiology*, **2019**, 10, 976 | 4.6 | 12 |
| 172 | Genotype-phenotype association analysis identifies the role of β-globin genes in modulating disease severity of β-thalassaemia intermedia in Sri Lanka. *Scientific Reports*, **2019**, 9, 10116 | 4.9 | 7 |
| 171 | The role of WNK in modulation of KCl cotransport activity in red cells from normal individuals and patients with sickle cell anaemia. *Pflugers Archiv European Journal of Physiology*, **2019**, 471, 1539-1549 | 4.6 | 2 |
| 170 | Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia. *Blood*, **2019**, 134, 615-615 | 2.2 | 3 |
| 169 | End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. *Blood Advances*, **2019**, 3, 3982-4001 | 7.8 | 25 |
| 168 | Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 6 |
| 167 | EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. *HemaSphere*, **2019**, 3, e208 | 0.3 | 7 |
| 166 | Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. *American Journal of Hematology*, **2019**, 94, 149-161 | 7.1 | 35 |
| 165 | A gain of function variant in PIEZO1 (E756del) and sickle cell disease. *Haematologica*, **2019**, 104, e91-e93 | 6.6 | 12 |
| 164 | The effect of xanthine oxidase and hypoxanthine on the permeability of red cells from patients with sickle cell anemia. *Physiological Reports*, **2018**, 6, e13626 | 2.6 | 2 |
| 163 | How I manage red cell transfusions in patients with sickle cell disease. *British Journal of Haematology*, **2018**, 180, 607-617 | 4.5 | 14 |
| 162 | Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction. *Haematologica*, **2018**, 103, 1136-1142 | 6.6 | 14 |
| 161 | Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. *British Journal of Haematology*, **2018**, 182, 567-578 | 4.5 | 18 |
| 160 | Lipid metabolism in terminal erythropoiesis. *Blood*, **2018**, 131, 2872-2874 | 2.2 | 1 |
| 159 | Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial. *Trials*, **2018**, 19, 55 | 2.8 | 11 |
| 158 | A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. *PLoS ONE*, **2018**, 13, e0197927 | 3.7 | 11 |

| | | | |
|---|---|---|---|
| 157 | Heterogeneity of respiratory disease in children and young adults with sickle cell disease. *Thorax*, **2018**, 73, 575-577 | 7.3 | 10 |
| 156 | High body mass index in children with sickle cell disease: a retrospective single-centre audit. *BMJ Paediatrics Open*, **2018**, 2, e000302 | 2.4 | 5 |
| 155 | : a genetic model of fetal hemoglobin in sickle cell disease. *Blood Advances*, **2018**, 2, 235-239 | 7.8 | 21 |
| 154 | An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom. *JIMD Reports*, **2017**, 36, 99-107 | 1.9 | 12 |
| 153 | Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 1561-1573 | 59.2 | 561 |
| 152 | Prasugrel hydrochloride for the treatment of sickle cell disease. *Expert Opinion on Investigational Drugs*, **2017**, 26, 865-872 | 5.9 | 8 |
| 151 | Recommendations regarding splenectomy in hereditary hemolytic anemias. *Haematologica*, **2017**, 102, 1304-1313 | 6.6 | 77 |
| 150 | Blood Transfusion in the Management of Patients with Haemoglobinopathies **2017**, 330-340 | | |
| 149 | Associations between environmental factors and hospital admissions for sickle cell disease. *Haematologica*, **2017**, 102, 666-675 | 6.6 | 18 |
| 148 | Update review of the acute porphyrias. *British Journal of Haematology*, **2017**, 176, 527-538 | 4.5 | 74 |
| 147 | Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. *Thrombosis and Haemostasis*, **2017**, 117, 580-588 | 7 | 13 |
| 146 | Newborn screening for haematological disorders. *Paediatrics and Child Health (United Kingdom)*, **2017**, 27, 500-505 | 0.6 | |
| 145 | Autoimmune Liver Disease in Children with Sickle Cell Disease. *Journal of Pediatrics*, **2017**, 189, 79-85.e2 | 3.6 | 16 |
| 144 | The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype). *British Journal of Haematology*, **2017**, 179, 256-265 | 4.5 | 2 |
| 143 | Are the risks of treatment to cure a child with severe sickle cell disease too high?. *BMJ, The*, **2017**, 359, j5250 | 5.9 | 6 |
| 142 | Early Markers of Sickle Nephropathy in Children With Sickle Cell Anemia Are Associated With Red Cell Cation Transport Activity. *HemaSphere*, **2017**, 1, e2 | 0.3 | 4 |
| 141 | The significance of inadequate transcranial Doppler studies in children with sickle cell disease. *PLoS ONE*, **2017**, 12, e0181681 | 3.7 | 7 |
| 140 | Prasugrel for Sickle Cell Vaso-Occlusive Events. *New England Journal of Medicine*, **2016**, 375, 185-6 | 59.2 | 6 |

| | | | |
|---|---|---|---|
| 139 | Extracranial internal carotid artery stenosis in children with sickle cell disease - Which transducer, what measurement?. *Ultrasound*, **2016**, 24, 86-93 | 1.3 | |
| 138 | Airway and alveolar nitric oxide production, lung function, and pulmonary blood flow in sickle cell disease. *Pediatric Research*, **2016**, 79, 313-7 | 3.2 | 7 |
| 137 | A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. *New England Journal of Medicine*, **2016**, 374, 625-35 | 59.2 | 96 |
| 136 | Lung function, transfusion, pulmonary capillary blood volume and sickle cell disease. *Respiratory Physiology and Neurobiology*, **2016**, 222, 6-10 | 2.8 | 12 |
| 135 | Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. *Blood*, **2016**, 128, 2318-2318 | 2.2 | 2 |
| 134 | Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. *Pediatric Blood and Cancer*, **2016**, 63, 299-305 | 3 | 13 |
| 133 | Longitudinal assessment of lung function in children with sickle cell disease. *Pediatric Pulmonology*, **2016**, 51, 717-23 | 3.5 | 28 |
| 132 | Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anemia. *Haematologica*, **2016**, 101, e469-e472 | 6.6 | 3 |
| 131 | Haemoglobinopathies and the rheumatologist. *Rheumatology*, **2016**, 55, 2109-2118 | 3.9 | 13 |
| 130 | ParentsŒ Experiences of Receiving the Initial Positive Newborn Screening (NBS) Result for Cystic Fibrosis and Sickle Cell Disease. *Journal of Genetic Counseling*, **2016**, 25, 1215-1226 | 2.5 | 24 |
| 129 | How benign is sickle cell trait?. *EBioMedicine*, **2016**, 11, 21-22 | 8.8 | 12 |
| 128 | 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. *Pediatric Blood and Cancer*, **2015**, 62, 1427-36 | 3 | 24 |
| 127 | Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. *Nature Communications*, **2015**, 6, 8085 | 17.4 | 174 |
| 126 | Environmental determinants of severity in sickle cell disease. *Haematologica*, **2015**, 100, 1108-16 | 6.6 | 61 |
| 125 | Haemoglobin and the Inherited Disorders of Globin Synthesis **2015**, 72-97 | | 2 |
| 124 | The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease. *Haematologica*, **2015**, 100, 595-600 | 6.6 | 14 |
| 123 | Prevention of Morbidity in sickle cell disease--qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. *Trials*, **2015**, 16, 376 | 2.8 | 7 |
| 122 | Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. *JIMD Reports*, **2015**, 22, 57-65 | 1.9 | 41 |

| | | | |
|---|---|---|---|
| 121 | Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy. *Blood*, **2015**, 126, 993-993 | 2.2 | 2 |
| 120 | A Comprehensive Next Generation Sequencing Gene Panel Focused on Unexplained Anemia. *Blood*, **2015**, 126, 946-946 | 2.2 | 1 |
| 119 | To begin at the beginning: sickle cell disease in Africa. *Lancet Haematology,the*, **2014**, 1, e50-1 | 14.6 | 4 |
| 118 | Nontraumatic extradural hematoma in sickle cell anemia: a rare neurological complication not to be missed. *American Journal of Hematology*, **2014**, 89, 225-7 | 7.1 | 18 |
| 117 | Managing the burden of sickle-cell disease in Africa. *Lancet Haematology,the*, **2014**, 1, e11-2 | 14.6 | 2 |
| 116 | Management of sickle cell disease in the community. *BMJ, The*, **2014**, 348, g1765 | 5.9 | 37 |
| 115 | The spleen and sickle cell disease: the sick(led) spleen. *British Journal of Haematology*, **2014**, 166, 165-76 | 4.5 | 125 |
| 114 | The haemoglobinopathies **2014**, 550-559 | | |
| 113 | Vitamin D deficiency and its correction in children with sickle cell anaemia. *Annals of Hematology*, **2014**, 93, 2051-6 | 3 | 14 |
| 112 | Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. *European Journal of Haematology*, **2014**, 92, 249-55 | 3.8 | 7 |
| 111 | Urinary excretion of porphyrins, porphobilinogen and □aminolaevulinic acid following an attack of acute intermittent porphyria. *Journal of Clinical Pathology*, **2014**, 67, 60-5 | 3.9 | 33 |
| 110 | Airways obstruction and pulmonary capillary blood volume in children with sickle cell disease. *Pediatric Pulmonology*, **2014**, 49, 716-22 | 3.5 | 23 |
| 109 | Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. *Journal of Physiology*, **2014**, 592, 4039-49 | 3.9 | 19 |
| 108 | A Novel Alpha Specrtin Mutation Causing Severe Innefective Erythropoiesis. *Blood*, **2014**, 124, 4002-4002 | 2.2 | 1 |
| 107 | Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization/tandem mass spectrometry. *Biomedical Chromatography*, **2013**, 27, 267-72 | 1.7 | 12 |
| 106 | Newborn screening for haematological disorders. *Paediatrics and Child Health (United Kingdom)*, **2013**, 23, 472-479 | 0.6 | 2 |
| 105 | Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia. *British Journal of Haematology*, **2013**, 160, 259-61 | 4.5 | 16 |
| 104 | The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. *Lancet, The*, **2013**, 381, 930-8 | 40 | 155 |

| | | | |
|---|---|---|---|
| 103 | Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Annals of Clinical Biochemistry*, **2013**, 50, 217-23 | 2.2 | 68 |
| 102 | A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease. *Journal of Physiology*, **2013**, 591, 1463-74 | 3.9 | 14 |
| 101 | Morbidity pattern of sickle cell disease in India: a single centre perspective. *Indian Journal of Medical Research*, **2013**, 138, 288-90 | 2.9 | 4 |
| 100 | The conductance of red blood cells from sickle cell patients: ion selectivity and inhibitors. *Journal of Physiology*, **2012**, 590, 2095-105 | 3.9 | 28 |
| 99 | Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry. *Biomedical Chromatography*, **2012**, 26, 1033-40 | 1.7 | 7 |
| 98 | Biomarkers in sickle cell disease. *British Journal of Haematology*, **2012**, 156, 433-45 | 4.5 | 79 |
| 97 | Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. *Cell Calcium*, **2012**, 51, 51-6 | 4 | 71 |
| 96 | Acute intermittent porphyria: fatal complications of treatment. *Clinical Medicine*, **2012**, 12, 293-4 | 1.9 | 20 |
| 95 | Changing pattern of hospital admissions of children with sickle cell disease over the last 50 years. *Journal of Pediatric Hematology/Oncology*, **2011**, 33, 491-5 | 1.2 | 9 |
| 94 | Soluble CD163 levels in children with sickle cell disease. *British Journal of Haematology*, **2011**, 153, 105-10 | 4.5 | 11 |
| 93 | ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. *American Journal of Hematology*, **2011**, 86, 72-5 | 7.1 | 24 |
| 92 | The safety and efficacy of hydroxycarbamide in infants with sickle cell anemia. *Expert Review of Hematology*, **2011**, 4, 407-9 | 2.8 | 1 |
| 91 | Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia. *Archives of Disease in Childhood*, **2011**, 96, 1082-4 | 2.2 | 18 |
| 90 | The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype). *Anemia*, **2011**, 2011, 248527 | 1.6 | 19 |
| 89 | Role of calcium in phosphatidylserine externalisation in red blood cells from sickle cell patients. *Anemia*, **2011**, 2011, 379894 | 1.6 | 15 |
| 88 | The rationale for using hydroxycarbamide in the treatment of sickle cell disease. *Haematologica*, **2011**, 96, 488-91 | 6.6 | 30 |
| 87 | Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical Trial. *Blood*, **2011**, 118, 9-9 | 2.2 | 2 |
| 86 | Significant haemoglobinopathies: guidelines for screening and diagnosis. *British Journal of Haematology*, **2010**, 149, 35-49 | 4.5 | 159 |

| | | | |
|---|---|---|---|
| 85 | Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease. *British Journal of Haematology*, **2010**, 149, 289-91 | 4.5 | 9 |
| 84 | Outcome of adults with sickle cell disease admitted to critical care - experience of a single institution in the UK. *British Journal of Haematology*, **2010**, 150, 610-3 | 4.5 | 16 |
| 83 | Outcome of children with sickle cell disease admitted to intensive care - a single institution experience. *British Journal of Haematology*, **2010**, 150, 614-7 | 4.5 | 7 |
| 82 | Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype). *Blood Cells, Molecules, and Diseases*, **2010**, 45, 46-52 | 2.1 | 15 |
| 81 | Sickle-cell disease. *Lancet, The*, **2010**, 376, 2018-31 | 40 | 1203 |
| 80 | Extracranial internal carotid arterial disease in children with sickle cell anemia. *Haematologica*, **2010**, 95, 1287-92 | 6.6 | 42 |
| 79 | Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. *Blood*, **2010**, 115, 2329-30 | 10.2 | 22 |
| 78 | A retrospective analysis of outcome of pregnancy in patients with acute porphyria. *Journal of Inherited Metabolic Disease*, **2010**, 33, 591-6 | 5.4 | 21 |
| 77 | Triose phosphate isomerase deficiency associated with two novel mutations in TPI gene. *European Journal of Haematology*, **2010**, 85, 170-3 | 3.8 | 8 |
| 76 | Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy. *Blood*, **2010**, 116, 4813-4813 | 2.2 | |
| 75 | Orbital compression syndrome in sickle cell crisis. *Klinische Padiatrie*, **2009**, 221, 308-9 | 0.9 | 4 |
| 74 | The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia. *Annals of Hematology*, **2009**, 88, 529-33 | 3 | 11 |
| 73 | Stroke prevention in the young child with sickle cell anaemia. *Annals of Hematology*, **2009**, 88, 943-6 | 3 | 4 |
| 72 | Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anaemia undergoing moderate risk surgery. *British Journal of Haematology*, **2009**, 144, 453-4 | 4.5 | 3 |
| 71 | Neonatal screening for haematological disorders. *Paediatrics and Child Health (United Kingdom)*, **2009**, 19, 372-376 | 0.6 | |
| 70 | Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial. *Haematologica*, **2009**, 94, 1006-10 | 6.6 | 40 |
| 69 | Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. *Blood*, **2009**, 114, 742-3; author reply 743-4 | 2.2 | 33 |
| 68 | Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease.. *Blood*, **2009**, 114, 2560-2560 | 10.2 | |

| | | | |
|---|---|---|---|
| 67 | The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. *British Journal of Haematology*, **2008**, 143, 589-92 | 4.5 | 15 |
| 66 | Transcranial Doppler scanning and the assessment of stroke risk in children with HbSC [corrected] disease. *Archives of Disease in Childhood*, **2008**, 93, 138-41 | 2.2 | 23 |
| 65 | A simple index using age, hemoglobin, and aspartate transaminase predicts increased intracerebral blood velocity as measured by transcranial Doppler scanning in children with sickle cell anemia. *Pediatrics*, **2008**, 121, e1628-32 | 7.4 | 27 |
| 64 | Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. *British Journal of Haematology*, **2008**, 140, 206-9 | 4.5 | 26 |
| 63 | Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. *American Journal of Hematology*, **2008**, 83, 714-6 | 7.1 | 10 |
| 62 | Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?. *Prenatal Diagnosis*, **2007**, 27, 104-10 | 3.2 | 24 |
| 61 | Temporal relationship of asthma to acute chest syndrome in sickle cell disease. *Pediatric Pulmonology*, **2007**, 42, 103-6 | 3.5 | 52 |
| 60 | Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia. *Pediatric Pulmonology*, **2007**, 42, 272-6 | 3.5 | 36 |
| 59 | The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. *British Journal of Haematology*, **2007**, 136, 844-8 | 4.5 | 28 |
| 58 | Circulating DNA: a potential marker of sickle cell crisis. *British Journal of Haematology*, **2007**, 139, 331-6 | 4.5 | 18 |
| 57 | Peak expiratory flow in Afro-Caribbean children with and without sickle cell anaemia. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 96, 1308-10 | 3.1 | 1 |
| 56 | Age-related changes in adaptation to severe anemia in childhood in developing countries. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 9440-4 | 11.5 | 45 |
| 55 | Is routine molecular screening for common alpha-thalassaemia deletions necessary as part of an antenatal screening programme?. *Journal of Medical Screening*, **2007**, 14, 60-1 | 1.4 | 6 |
| 54 | Diagnosis and management of congenital haemolytic anaemia. *Clinical Medicine*, **2007**, 7, 625-9 | 1.9 | 2 |
| 53 | Lung gas transfer in children with sickle cell anaemia. *Respiratory Physiology and Neurobiology*, **2007** , 158, 70-4 | 2.8 | 5 |
| 52 | Ethnicity questions and antenatal screening for sickle cell/thalassaemia [EQUANS] in England: a randomised controlled trial of two questionnaires. *Ethnicity and Health*, **2006**, 11, 169-89 | 2.2 | 19 |
| 51 | Impact of acute chest syndrome on lung function of children with sickle cell disease. *Journal of Pediatrics*, **2006**, 149, 17-22 | 3.6 | 51 |
| 50 | Trials in sickle cell disease. *Pediatric Neurology*, **2006**, 34, 450-8 | 2.9 | 39 |

| | | | |
|---|---|---|---|
| 49 | Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. *Blood*, **2006**, 108, 2846-9 | 2.2 | 80 |
| 48 | Cell-free DNA levels in pregnancies at risk of sickle-cell disease and significant ethnic variation. *British Journal of Haematology*, **2006**, 135, 738-41 | 4.5 | 13 |
| 47 | Rituximab in Children with Autoimmune Thrombocytopenia Complicating Underlying Congenital or Acquired Immunodeficiency State.. *Blood*, **2006**, 108, 3977-3977 | 2.2 | 1 |
| 46 | The Impact of Local Air Quality on the Number of Hospital Admissions with Acute Pain in Sickle Cell Disease within an Urban Environment.. *Blood*, **2006**, 108, 3790-3790 | 2.2 | |
| 45 | Cell Free Fetal and Total DNA Levels in Pregnancies at Risk of Sickle Cell Disease and Significant Ethnic Variation.. *Blood*, **2006**, 108, 3791-3791 | 2.2 | |
| 44 | Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. *Cochrane Database of Systematic Reviews*, **2005**, CD004450 | | 14 |
| 43 | The measurement of urinary hydroxyurea in sickle cell anaemia. *British Journal of Haematology*, **2005**, 130, 138-44 | 4.5 | 10 |
| 42 | Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia. *British Journal of Haematology*, **2005**, 130, 297-309 | 4.5 | 113 |
| 41 | Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. *British Journal of Haematology*, **2005**, 131, 530-3 | 4.5 | 50 |
| 40 | Exhaled carbon monoxide levels in children with sickle cell disease. *European Journal of Pediatrics*, **2005**, 164, 162-5 | 4.1 | 27 |
| 39 | Introduction of Routine Screening for Cerebrovascular Abnormailities in Sickle Cell Disease (SCD) Using Transcranial Doppler Ultrasonography (TCD).. *Blood*, **2005**, 106, 3786-3786 | 2.2 | |
| 38 | Dehydrated hereditary stomatocytosis is associated with neonatal hepatitis. *British Journal of Haematology*, **2004**, 126, 272-6 | 4.5 | 9 |
| 37 | Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. *British Journal of Haematology*, **2004**, 127, 607-8 | 4.5 | 11 |
| 36 | Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme. *International Journal of Laboratory Hematology*, **2004**, 26, 37-42 | | 4 |
| 35 | The genetic basis of the interaction between pyrimidine 5′-nucleotidase I deficiency and hemoglobin E. *Nucleosides, Nucleotides and Nucleic Acids*, **2004**, 23, 1261-3 | 1.4 | 6 |
| 34 | Epstein-Barr virus-related post-transplant lymphoproliferative disorder with t(9;14)(p11-12;q32). *Cancer Genetics and Cytogenetics*, **2003**, 142, 134-6 | | 8 |
| 33 | Pyrimidine 5′-nucleotidase deficiency. *British Journal of Haematology*, **2003**, 120, 375-83 | 4.5 | 45 |
| 32 | Guidelines for the management of the acute painful crisis in sickle cell disease. *British Journal of Haematology*, **2003**, 120, 744-52 | 4.5 | 164 |

| | | | |
|---|---|---|---|
| 31 | Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of beta-thalassaemia trait. *British Journal of Haematology*, **2003**, 123, 353-8 | 4.5 | 14 |
| 30 | Lamin B-receptor mutations in Pelger-Hu anomaly. *British Journal of Haematology*, **2003**, 123, 542-4 | 4.5 | 42 |
| 29 | Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. *Human Genetics*, **2002**, 111, 360-7 | 6.3 | 226 |
| 28 | Molecular analysis of the beta-globin gene cluster in the Niokholo Mandenka population reveals a recent origin of the beta(S) Senegal mutation. *American Journal of Human Genetics*, **2002**, 70, 207-23 | 11 | 98 |
| 27 | Genetic basis of hemolytic anemia caused by pyrimidine 5 nucleotidase deficiency. *Blood*, **2001**, 97, 3327-32 | 7.3 | 48 |
| 26 | Factor V Leiden mutation screened by PCR and detected with lanthanide-labeled probes. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 291-7 | | 5 |
| 25 | A second case of Hb Renert [beta133(H11)Val --> Ala]. *Hemoglobin*, **2001**, 25, 337-40 | 0.6 | 3 |
| 24 | Hemoglobin F and hemoglobin E/beta-thalassemia. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 567-72 | | 14 |
| 23 | FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. *British Journal of Haematology*, **2000**, 111, 190-5 | 4.5 | 227 |
| 22 | Are aberrant BCR--ABL transcripts more common than previously thought?. *British Journal of Haematology*, **2000**, 111, 1109-11 | 4.5 | 28 |
| 21 | Born to clot: the European burden. *British Journal of Haematology*, **1999**, 105, 564-566 | 4.5 | 96 |
| 20 | Minisatellite mutational processes reduce F st estimates. *Human Genetics*, **1999**, 105, 567-576 | 6.3 | 12 |
| 19 | Reduced soluble transferrin receptor concentrations in acute malaria in Vanuatu. *American Journal of Tropical Medicine and Hygiene*, **1999**, 60, 875-8 | 3.2 | 23 |
| 18 | Born to clot: the European burden **1999**, 105, 564 | | 2 |
| 17 | Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley anemia. *Annals of the New York Academy of Sciences*, **1998**, 850, 100-9 | 6.5 | 44 |
| 16 | The hemoglobin E syndromes. *Annals of the New York Academy of Sciences*, **1998**, 850, 334-43 | 6.5 | 78 |
| 15 | Nontransfusional iron overload in thalassemia. Association with hereditary hemochromatosis. *Annals of the New York Academy of Sciences*, **1998**, 850, 490-4 | 6.5 | 16 |
| 14 | Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. *British Journal of Haematology*, **1998**, 101, 416-9 | 4.5 | 72 |

| | | | |
|---|---|---|---|
| 13 | Alpha thalassaemia is associated with increased soluble transferrin receptor levels. *British Journal of Haematology*, **1998**, 103, 365-9 | 4.5 | 59 |
| 12 | Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. *American Journal of Human Genetics*, **1998**, 62, 1258-60 | 11 | 206 |
| 11 | Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. *Lancet, The*, **1997**, 350, 491-2 | 40 | 61 |
| 10 | Global distribution of the CCR5 gene 32-basepair deletion. *Nature Genetics*, **1997**, 16, 100-3 | 36.3 | 457 |
| 9 | Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. *British Journal of Haematology*, **1997**, 96, 490-2 | 4.5 | 11 |
| 8 | Erythroblastic Inclusions in Dominantly Inherited Thalassemias. *Blood*, **1997**, 89, 322-328 | 2.2 | 41 |
| 7 | Evidence for a single origin of factor V Leiden. *British Journal of Haematology*, **1996**, 92, 1022-5 | 4.5 | 53 |
| 6 | The population genetics of factor V Leiden (Arg506Gln). *British Journal of Haematology*, **1996**, 95, 579-86 | 4.5 | 162 |
| 5 | The metabolites of nitric oxide in sickle-cell disease. *British Journal of Haematology*, **1995**, 91, 834-7 | 4.5 | 64 |
| 4 | Use of splenic ultrasound: a new wave for immune thrombocytopenic purpura. *Journal of Clinical Pathology*, **1994**, 47, 414-7 | 3.9 | 0 |
| 3 | Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. *BMJ: British Medical Journal*, **1993**, 306, 841-2 | | 138 |
| 2 | Blood Transfusion in the Management of Patients with Haemoglobinopathies314-321 | | |
| 1 | Haemoglobin and the Inherited Disorders of Globin Synthesis83-108 | | 4 |